India Pharmaceutical News

Related Pharmaceuticals Industry News

• March 2024: Novo Nordisk invested USD 556 million to expand its production capabilities in China and help it meet the global drug demand. The project will involve a new plant producing active pharmaceutical ingredients, including those used in the company's GLP-1 products.
• January 2024: AstraZeneca invested USD 26.5 million to build a production line for metformin hydrochloride and dapagliflozin in China. The company is expanding its operations to manufacture a diabetes drug approved for the Chinese market.

• January 2024: Eisai Co. Ltd received marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of Fycompa (perampanel), its in-house discovered anti-epileptic drug (AED), in Japan as an alternative therapy when oral administration is temporarily not possible.
• October 2023: Xenon Pharmaceuticals announced results from the Phase IIb X-TOLE study, which showed that an investigational potassium channel opener XEN1101 could safely reduce seizure burden in adults with focal epilepsy.

• January 2024: Ipsen revealed the positive result from the AboLiSh study about Dysport (abobotulinumtoxinA) for spasticity treatment at the 7th international conference, TOXINS, in Berlin, Germany.
• June 2022: Amneal Pharmaceuticals Inc. launched LYVISPAH, a baclofen oral granule (5, 10, and 20 mg) specialty product approved by the US Food and Drug Administration for the treatment of spasticity related to multiple sclerosis and other spinal cord disorders.

• October 2023: Immunic Inc. presented positive data from a Phase 1b clinical trial of IMU-856, a potential new treatment for celiac disease. This orally administered medication represents a significant development in the field. IMU-856 targets SIRT6, a protein not previously explored in celiac disease treatment. This approach offered promise beyond existing therapies and was presented at the United European Gastroenterology Week (UEGW) 2023.
• June 2023: Takeda collaborated with Celiac Disease Foundation, actively recruiting participants for trials testing TAK-062 and TAK-101 promising therapies. This development signified a major step forward in celiac disease treatment research, offering hope for millions managing the condition.

• March 2024: Otsuka Pakistan Limited initiated the renovation and upgrade of its glucose IV solutions manufacturing facilities, focusing on products such as glucose IV to enhance product quality.
• March 2024: Baxter published the US Hospital Products Availability Report, highlighting the availability of key products, including glucose 5% IV solution.

• January 2024: Ildong Pharmaceutical announced a strategic move by signing an eye drop co-promotion agreement with Hanlim Pharm. This collaboration aims to facilitate Ildong's entry into the OTC (over-the-counter) segment of the ophthalmology market. The agreement spotlights Numaren Eye Drops, a hypromellose-dextran formulation designed to address dry eyes and tear production deficiencies.
• August 2023: The Drug Administration of Vietnam and the Ministry of Health licensed the import of 17,010 bags of dextran infusion. These imports were specifically for infirmaries lacking circulation registration, which aligned with prevailing regulations. The Ministry of Health emphasized dextran's significance as a high molecular weight solution, particularly in treating patients with dengue shock syndrome.

• September 2024: Aculys Pharma Inc. submitted a New Drug Application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for diazepam nasal spray, an antiepileptic drug being developed for the treatment of status epilepticus or epileptic seizures that may lead to status epilepticus.
• March 2024: The Epilepsy Foundation partnered with Iaso Venture to establish the Iaso NeuroImpact Fund. This innovative fund serves as a cornerstone for advancing the development of pioneering therapeutics aimed at revolutionizing the landscape of care for epilepsy and seizure disorders.

• September 2024: Danone unveiled plans to make a EUR 20 million investment in its Lalru, Punjab, nutrition facility in India over the next four years. This investment aims to enhance Danone's production capabilities in early-life and medical nutrition product areas where the company holds a global leadership position.
• May 2024: Danone invested EUR 70 million (USD 76 million) to enhance its Steenvoorde production facility in France. This investment aims to strengthen Danone's specialized nutrition category, particularly by optimizing the capacity for its oral nutrition supplements. With these upgrades, the facility is set to produce 20 million liters of nutrition products by 2026, catering to patients with critical health conditions, including cancer.

• July 2024: The United States Food and Drug Administration approved four whey protein hydrolysates from Arla Foods Ingredients for use in early-life nutrition. These ingredients, Peptigen and Lacprodan, are designed to aid in allergy management and promote gut comfort.
• October 2023: Arla Foods Ingredients upgraded its Porteña facility in Argentina to meet the rising global demand for high-quality whey ingredients, with a particular focus on Latin America. A key enhancement was the installation of a new drying tower, which boosted the capacity for whey permeate powder and enabled the production of infant-formula-grade proteins, such as alpha-lactalbumin.

• June 2024: Eli Lilly and Company presented positive results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, at the European Association for the Study of the Liver (EASL) Congress 2024 to evaluate the investigational use of tirzepatide in adults with biopsy-proven metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis.
• March 2024: Ionis Pharmaceuticals Inc. reported positive results from a Phase 2 study of ION224, an investigational DGAT2 antisense inhibitor with both doses (120 mg and 90 mg) in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).